Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial
Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e563-e564
DOI: 10.1055/s-0044-1789634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von J. Schattenberg und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Elafibranor, a dual peroxisome proliferator-activated receptor-α/δ agonist, is being investigated in primary biliary cholangitis (PBC). In the phase III ELATIVE trial (NCT04526665), elafibranor efficacy was assessed in patients with PBC with inadequate response or intolerance to ursodeoxycholic acid. PBC is characterised by elevated alkaline phosphatase (ALP) levels. As the disease progresses, total bilirubin (TB) levels increase. ALP and TB have prognostic value and form the basis of several clinical biochemical response criteria.
Aim
The primary endpoint (POISE trial endpoint criteria: ALP
Zitieren
APA
Schattenberg, J., Sonderup, M., Spearman, W., Calvaruso, V., Antunes, N., Shu, J., Zein, C. O., & Kowdley, K. V. (2024). Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial. Zeitschrift für Gastroenterologie, 62(09), e563-e564. https://doi.org/10.1055/s-0044-1789634
Vancouver
Schattenberg J, Sonderup M, Spearman W, Calvaruso V, Antunes N, Shu J, et al. Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial. Zeitschrift für Gastroenterologie. 2024;62(09):e563-e564. doi:10.1055/s-0044-1789634
BibTeX
@article{Schattenberg2024,
author = {Schattenberg, J. and Sonderup, M. and Spearman, W. and Calvaruso, V. and Antunes, N. and Shu, J. and Zein, C. O. and Kowdley, K. V.},
title = {Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial},
journal = {Zeitschrift für Gastroenterologie},
year = {2024},
volume = {62},
number = {09},
pages = {e563--e564},
doi = {10.1055/s-0044-1789634}
}
EUVIMED